1 |
Jones PB, Barnes TR, Davies L, et al., Randomized Controlled Trial of the Effect on Quality of Life of Second vs First-Generation Antipsychotic Drugs in Schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS1). Arch Gen Psychiatry 2006; 63: 1079-1087.
DOI
ScienceOn
|
2 |
Casey DE. Extrapyramidal syndromes; epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5: 1-12.
|
3 |
Miller CH, Mohr F, Umbricht D, et al., The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59: 69-75.
DOI
ScienceOn
|
4 |
Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651.
DOI
ScienceOn
|
5 |
Gervin M, Browne S, Garavan J, et al., Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405-409.
DOI
ScienceOn
|
6 |
Leucht S, Corves C, Arbter D, et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
DOI
ScienceOn
|
7 |
Miller DD, Caroff SN, Davis SM, et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-288
DOI
ScienceOn
|
8 |
Kane JM, Fleischhacker WW, Hansen L, et al., Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009; 70: 627-643.
DOI
ScienceOn
|
9 |
Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989; 8: 691-709.
|
10 |
Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psycchiatry 1989; 50: 329-338.
|
11 |
Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13: S49-S57.
|
12 |
The American Psychiatric Publishing. Textbook of Psychiatry, 3th Edition.
|
13 |
The American Psychiatric Publishing. Textbook of Psychopharmacology, 4th Edition. Chapter34. Drug to Treat Extrapyramidal Side Effects.
|
14 |
Xiang YT, Wang CY, Si TM, et al., Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009. Pharmacopsychiatry 2011; 44: 114-118.
DOI
ScienceOn
|
15 |
De Hert M, Wampers M, van WR, et al., Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 2007; 152: 165-173.
DOI
ScienceOn
|
16 |
Loga-Zec S, Loga S. Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH). Psychiatr Danub 2011; 23: 60-63.
|
17 |
Rummel-Kluge C, Komossa K, Schwarz S, et al., Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-tohead comparisons. Schizophr Bull 2012; 38: 167-177.
DOI
ScienceOn
|